دورية
Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the ‘1stFLOR’ Study
العنوان: | Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the ‘1stFLOR’ Study |
---|---|
المؤلفون: | Barraclough, Allison, Chong, Geoff, Gilbertson, Michael, Grigg, Andrew, Churilov, Leonid, Fancourt, Tineke, Ritchie, David, Koldej, Rachel, Agarwal, Rishu, Manos, Kate, Smith, Charmaine, Houdyk, Kristen, Hawking, Joanne, Hawkes, Eliza |
المصدر: | Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p1523-1523, 1p |
مستخلص: | Background: |
قاعدة البيانات: | Supplemental Index |
كن أول من يترك تعليقا!